HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Risk of leukaemia after chemotherapy in a case-control study in Moscow.

Abstract
In a case-control study of second primary cancers in Moscow, there were 165 cases and 294 controls, matched for site of first primary, duration of follow-up since first primary and relapse history. Of the cases, 18 were of acute, non-lymphocytic leukaemia (ANLL), with 39 matched controls. Risk of ANLL was assessed with respect to chemotherapy for the first primary tumour. The chemotherapeutic agents investigated were nitrogen mustard, cyclophosphamide, procarbazine, doxorubicin, bleomycin, vinblastine, vincristine, prednisone and combinations. Increased risks were associated with use of nitrogen mustard (odds ratio = 9.94, not significant), doxorubicin (odds ratio = 11.25, 0.1 > P > 0.05) and vincristine (odds ratio = 26.57, P < 0.05). Despite the small number of cases and potential confounding by other agents, these findings, together with those of previous studies, suggest that some non-alkylating agents may predispose to second malignancies.
AuthorsD G Zaridze, M A Arkadieva, N E Day, S W Duffy
JournalBritish journal of cancer (Br J Cancer) Vol. 67 Issue 2 Pg. 347-50 (Feb 1993) ISSN: 0007-0920 [Print] England
PMID8431364 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (adverse effects)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Case-Control Studies
  • Combined Modality Therapy
  • Female
  • Humans
  • Leukemia, Myeloid, Acute (chemically induced, epidemiology, etiology)
  • Leukemia, Radiation-Induced (epidemiology)
  • Male
  • Middle Aged
  • Moscow (epidemiology)
  • Radiotherapy (adverse effects)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: